Mohammad Alabdulrahman

Mohammad Alabdulrahman

Auto-generated profile, based on publicly available information

Mohammad Alabdulrahman

The Department of Surgery, RCSI University of Medicine and Health Sciences, Dublin, Ireland.

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2024 in Health Science Reports
Verified
Journal Article
Open access
MZMuhammad Jawad Zahid
Muhammad Jawad Zahid
PMParit T Mavani
Parit T Mavani
WAWireko Andrew Awuah
Wireko Andrew Awuah
MAMohammad Alabdulrahman
Mohammad Alabdulrahman
RPRachana Punukollu
Rachana Punukollu
TKTehreem Naseer Khan
Tehreem Naseer Khan
Background and Aims: The advent of 3D printing has revolutionized plastic surgery and prosthetic devices, providing personalized solutions for patients with traumatic injuries, deformities, and appearance‐related conditions. This review offers a comprehensive overview of 3D printing's applications, advantages, limitations, and future prospects in these fields.Methods: A literature search was conducted in PubMed, Google Scholar, and Scopus for studies on 3D printing in plastic surgery.Results: 3D printing has significantly contributed to personalized medical interventions, with benefits like enhanced design flexibility, reduced production time, and improved patient outcomes. Using computer‐aided design (CAD) software, precise models tailored to a patient's anatomy can be created, ensuring better fit, functionality, and comfort. 3D printing allows for intricate geometries, leading to improved aesthetic outcomes and patient‐specific prosthetic limbs and orthoses. The historical development of 3D printing, key milestones, and breakthroughs are highlighted. Recent progress in bioprinting and tissue engineering shows promising applications in regenerative medicine and transplantation. The integration of AI and automation with 3D printing enhances surgical planning and outcomes. Emerging trends in patient‐specific treatment planning and precision medicine are potential game‐changers. However, challenges like technical considerations, economic implications, and ethical issues exist. Addressing these challenges and advancing research in materials, design processes, and long‐term outcomes are crucial for widespread adoption.Conclusion: The review underscores the increasing adoption of 3D printing in healthcare and its impact on plastic surgery and prosthetic devices. It emphasizes the importance of evaluating the current state and addressing knowledge gaps through future research to foster further advancements

5 February 2026 in Current Oncology Reports
Verified
Journal Article
Open access
MAMohammad Alabdulrahman
Mohammad Alabdulrahman
GDGordon R. Daly
Gordon R. Daly
SNSindhuja Naidoo
Sindhuja Naidoo
LSLea Stuart
Lea Stuart
SASami Almasri
Sami Almasri
LYLeonie S. Young
Leonie S. Young
Purpose of Review: To examine recent advances in understanding breast cancer brain metastases (BCBM), with emphasis on metastatic mechanisms, tumour-microenvironment interactions, receptor discordance between primary breast tumours and brain metastases, diagnostic innovations, and therapeutic strategies. The review sought to clarify how these developments inform precision management and identify priorities for future research. Recent Findings: Studies implicate JAK–STAT signalling, homologous recombination deficiency, c-MYC , PI3K/AKT/mTOR, and RET in BCBM progression. Tumour cells adapt via neuronal mimicry, metabolic reprogramming, and crosstalk with astrocytes and microglia. Receptor discordance between primary breast cancers and brain metastases occurs in up to one-third of cases and may alter systemic therapy. Emerging tools including liquid biopsy, spatial transcriptomics, and radiomics offer minimally invasive approaches for molecular profiling, spatial mapping, and imaging-based phenotyping to guide personalised management. Machine learning supports prognostication and imaging interpretation, though external validation is limited. Summary: BCBM reflect complex tumour-brain interactions. Advances in molecular understanding and diagnostics are beginning to inform the development of targeted therapies. Future work may benefit from integrating cancer neuroscience with computational modelling, standardise diagnostic platforms, and test the survival impact of receptor reassessment in prospective trials.